advertisement
11.16 Vehicles, delivery systems, pharmacokinetics, formulation (17)
Showing records 1 to 17
Search within classification 11.16 Vehicles, delivery systems, pharmacokinetics, formulation26671 Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations
Sullivan-Mee M; Pensyl D; Alldredge B; Halverson K; Gerhardt G; Qualls C
Journal of Ocular Pharmacology and Therapeutics 2010; 26: 355-360
26672 Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension
Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
Journal of Ocular Pharmacology and Therapeutics 2010; 26: 287-292
26875 A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension
Hommer A
Drugs of Today 2010; 46: 409-416
26547 IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma
Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
Current Medical Research and Opinion 2010; 26: 1905-1913
26669 Ion-and pH-activated novel in-situ gel system for sustained ocular drug delivery
Gupta H; Velpandian T; Jain S
Journal of Drug Targeting 2010; 18: 499-505
26775 Numerical simulations of ethacrynic acid transport from precorneal region to trabecular meshwork
Lin CW; Yuan F
Annals of Biomedical Engineering 2010; 38: 935-944
26743 Enhancement of miotic potential of pilocarpine by tamarind gum based in-situ gelling ocular dosage form
Mehra GR; Manish M; Rashi S; Neeraj G; Mishra DN
Acta Pharmaceutica Sciencia 2010; 52: 145-154
26885 Impact of glaucoma medication on ocular tissue
Valente C; Iester M
Expert Review of Ophthalmology 2010; 5: 405-412
26675 Design and evaluation of thermoreversible in situ gelling system of forskolin for the treatment of glaucoma
Gupta S; Samanta MK
Pharmaceutical Development and Technology 2010; 15: 386-393
26695 A case study: Safety evaluation of ophthalmic drug-device combination products
Brown AP
International Journal of Toxicology 2010; 29: 118
26629 Anti-glaucomatic niosomal system: Recent trend in ocular drug delivery research
Paul S; Mondol R; Ranjit S; Maiti S
International Journal of Pharmacy and Pharmaceutical Sciences 2010; 2: 15-18
26747 Preservatives in eyedrops: The good, the bad and the ugly
Baudouin C; Labbe A; Liang H; Pauly A; Brignole-Baudouin F
Progress in Retinal and Eye Research 2010; 29: 312-334
26344 Study of alpha-lipoic acid penetration in the human aqueous after topical administration
Cagini C; Leontiadis A; Ricci MA; Bartolini A; Dragoni A; Pellegrino RM
Clinical and Experimental Ophthalmology 2010; 38: 572-576
26904 Microchips and controlled-release drug reservoirs
Staples M
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 2010; 2: 400-417
26481 Optimization of benzalkonium chloride concentration in 0.0015% tafluprost ophthalmic solution from the points of ocular surface safety and preservative efficacy
Asada H; Takaoka-Shichijo Y; Nakamura M; Kimura A
Yakugaku Zasshi 2010; 130: 867-871
26473 Microbial contamination of nipradiol with and without benzalkonium chloride
Inoue K; Wakakura M; Miyanaga Y; Tomita G
Nippon Ganka Gakkai Zasshi 2010; 114: 604-611
26876 Promising complexes of acetazolamide for topical ocular administration
Granero GE; Longhi MR
Expert Opinion on Drug Delivery 2010; 7: 943-953
